000300255 001__ 300255
000300255 005__ 20250821121435.0
000300255 0247_ $$2pmid$$apmid:40177982
000300255 0247_ $$2ISSN$$a0020-7136
000300255 0247_ $$2ISSN$$a1097-0215
000300255 0247_ $$2doi$$a10.1002/ijc.35428
000300255 0247_ $$2altmetric$$aaltmetric:175923681
000300255 037__ $$aDKFZ-2025-00716
000300255 041__ $$aEnglish
000300255 082__ $$a610
000300255 1001_ $$0P:(DE-He78)0ee96cf24374ef9b87086e9395880af9$$aCooley, Victoria$$b0$$eFirst author$$udkfz
000300255 245__ $$aProspective evaluation of 92 protein biomarkers for early detection of endometrial cancer.
000300255 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000300255 3367_ $$2DRIVER$$aarticle
000300255 3367_ $$2DataCite$$aOutput Types/Journal article
000300255 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1749537008_29235
000300255 3367_ $$2BibTeX$$aARTICLE
000300255 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300255 3367_ $$00$$2EndNote$$aJournal Article
000300255 500__ $$a#EA:C020#LA:C020# / 2025 Aug 1;157(3):480-489
000300255 520__ $$aThe human epididymis protein 4 (HE4) remains the best available endometrial cancer (EC) biomarker; however, its discrimination between cases and cancer-free individuals is limited and might be improved when combined with other protein markers. We evaluated the discrimination capacity of 92 proteins as potential early detection biomarkers for EC in nested case-control studies in the European Prospective Investigation into Cancer and Nutrition (EPIC) (63 cases, 123 controls) and Janus (75 cases, 146 controls) cohorts, evaluating blood samples taken ≤2 years prior to diagnosis. Proteins were measured with the Olink Target 96 Oncology II panel assays. Areas under the receiver operating characteristic curves (AUCs) were calculated using logistic regression. The discrimination between cases and controls of top-performing proteins was modest (EPIC: HE4, CA125, CAIX, and S100A4; Janus: HE4, CA125, FURIN, CXCL13, and IL6; AUC range: 0.65 [S100A4], 0.76 [HE4, EPIC] within 0 to <12 months of blood collection) and decreased as the time between blood draw and cancer diagnosis increased (12-24 months AUC range: 0.49 [S100A4], 0.69 [CA125, Janus]). The combination of these other markers with HE4 did not improve discrimination. HE4 and other candidate proteins had limited discrimination between EC cases and controls and hence do not appear to be useful for early detection of this disease in women at average population risk.
000300255 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300255 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000300255 650_7 $$2Other$$abiomarkers
000300255 650_7 $$2Other$$aearly detection
000300255 650_7 $$2Other$$aendometrial cancer
000300255 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée Turzanski$$b1$$udkfz
000300255 7001_ $$0P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aMukama, Trasias$$b2
000300255 7001_ $$aNaudin, Sabine$$b3
000300255 7001_ $$00000-0001-5438-970X$$aPala, Valeria$$b4
000300255 7001_ $$aDossus, Laure$$b5
000300255 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b6
000300255 7001_ $$aOlsen, Karina Standahl$$b7
000300255 7001_ $$aSánchez, Maria-Jose$$b8
000300255 7001_ $$aIsraelsson, Pernilla$$b9
000300255 7001_ $$aAllen, Naomi$$b10
000300255 7001_ $$aLangseth, Hilde$$b11
000300255 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b12$$eLast author$$udkfz
000300255 773__ $$0PERI:(DE-600)1474822-8$$aDOI:10.1002/ijc.35428$$n3$$p480-489$$tInternational journal of cancer$$v157$$x0020-7136$$y2025
000300255 909CO $$ooai:inrepo02.dkfz.de:300255$$pVDB
000300255 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000300255 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000300255 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000300255 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000300255 9141_ $$y2025
000300255 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0ee96cf24374ef9b87086e9395880af9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300255 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300255 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000300255 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000300255 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300255 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300255 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300255 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300255 980__ $$ajournal
000300255 980__ $$aVDB
000300255 980__ $$aI:(DE-He78)C020-20160331
000300255 980__ $$aUNRESTRICTED